Abstract
Polo-like kinase 1 (PLK1) serves as a regulator of cell cycle progression and is overexpressed in various human cancer cells. PLK1 contains a conserved polo-box domain (PBD) as well as a kinase domain (KD), like other members of the PLK family. The PBDs of the PLK family interact with phosphopeptides that contain highly conserved Ser-pSer/pThr (S-pS/T) motifs and play significant roles in substrate recognition and subcellular localization. The PBD of PLK1 has been regarded as a promising therapeutic target for cancer therapy. In this study, we investigated whether the phosphopeptide derived from NCAPG2 has a high binding specificity for the PLK1 PDB over those other highly similar PBDs, including PLK2, PLK3, and PLK5. We showed that the PBDs of PLKs have different binding affinities against CDC25c-, PBIP-, and NCAPG2-derived phosphopeptides using the fluorescence polarization binding assay. Unlike CDC25c-phosphopeptide, NCAPG2-phosphopeptide specifically bound to the PLK1 PBD with nanomolar affinity (Kd ~ 48.68 nM), and its specificity was similar to that of the PBIP-derived phosphopeptide. Some of these phosphopeptide-PBD interactions can be explained by calculating the binding free energies using the Molecular Mechanics Poisson–Boltzmann surface area (MM/PBSA). Additionally, NCAPG2-phosphopeptide suppressed the proliferation of cancer cells. The NCAPG2-derived phosphopeptide can be applicable to the discovery of highly selective protein–protein interaction inhibitors targeting the PBD of PLK1.
This is a preview of subscription content, log in via an institution to check access.
References
Archambault V, Lepine G, Kachaner D (2015) Understanding the polo kinase machine. Oncogene 34:4799–4807
Arkin MR, Tang Y, Wells JA (2014) Small-molecule inhibitors of protein-protein interactions: progressing toward the reality. Chem Biol 21:1102–1114
Best RB, Zhu X, Shim J, Lopes PE, Mittal J, Feig M, Mackerell AD Jr (2012) Optimization of the additive CHARMM all-atom protein force field targeting improved sampling of the backbone phi, psi and side-chain chi(1) and chi(2) dihedral angles. J Chem Theory Comput 8:3257–3273
de Carcer G, Manning G, Malumbres M (2011) From Plk1 to Plk5: functional evolution of polo-like kinases. Cell Cycle 10:2255–2262
Fogolari F, Brigo A, Molinari H (2003) Protocol for MM/PBSA molecular dynamics simulations of proteins. Biophys J 85:159–166
Garcia-Alvarez B, de Carcer G, Ibanez S, Bragado-Nilsson E, Montoya G (2007) Molecular and structural basis of polo-like kinase 1 substrate recognition: implications in centrosomal localization. Proc Natl Acad Sci USA 104:3107–3112
Gutteridge RE, Ndiaye MA, Liu X, Ahmad N (2016) Plk1 inhibitors in cancer therapy: from laboratory to clinics. Mol Cancer Ther 15:1427–1435
Kim JH, Shim J, Ji MJ, Jung Y, Bong SM, Jang YJ, Yoon EK, Lee SJ, Kim KG, Kim YH, Lee C, Lee BI, Kim KT (2014) The condensin component NCAPG2 regulates microtubule-kinetochore attachment through recruitment of polo-like kinase 1 to kinetochores. Nat Commun 5:4588
Kim JH, Ku B, Lee KS, Kim SJ (2015) Structural analysis of the polo-box domain of human polo-like kinase 2. Proteins 83:1201–1208
Kollman PA, Massova I, Reyes C, Kuhn B, Huo S, Chong L, Lee M, Lee T, Duan Y, Wang W, Donini O, Cieplak P, Srinivasan J, Case DA, Cheatham TE 3rd (2000) Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. Acc Chem Res 33:889–897
Lee KS, Burke TR Jr, Park JE, Bang JK, Lee E (2015) Recent advances and new strategies in targeting Plk1 for anticancer therapy. Trends Pharmacol Sci 36:858–877
Liu Z, Sun Q, Wang X (2017) PLK1, a potential target for cancer therapy. Transl Oncol 10:22–32
Park SY, Park JE, Kim TS, Kim JH, Kwak MJ, Ku B, Tian L, Murugan RN, Ahn M, Komiya S, Hojo H, Kim NH, Kim BY, Bang JK, Erikson RL, Lee KW, Kim SJ, Oh BH, Yang W, Lee KS (2014) Molecular basis for unidirectional scaffold switching of human Plk4 in centriole biogenesis. Nat Struct Mol Biol 21:696–703
Phillips JC, Braun R, Wang W, Gumbart J, Tajkhorshid E, Villa E, Chipot C, Skeel RD, Kale L, Schulten K (2005) Scalable molecular dynamics with NAMD. J Comput Chem 26:1781–1802
Reindl W, Strebhardt K, Berg T (2008) A high-throughput assay based on fluorescence polarization for inhibitors of the polo-box domain of polo-like kinase 1. Anal Biochem 383:205–209
Reindl W, Graber M, Strebhardt K, Berg T (2009) Development of high-throughput assays based on fluorescence polarization for inhibitors of the polo-box domains of polo-like kinases 2 and 3. Anal Biochem 395:189–194
Steegmaier M, Hoffmann M, Baum A, Lenart P, Petronczki M, Krssak M, Gurtler U, Garin-Chesa P, Lieb S, Quant J, Grauert M, Adolf GR, Kraut N, Peters JM, Rettig WJ (2007) BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr Biol 17:316–322
Strebhardt K, Kneisel L, Linhart C, Bernd A, Kaufmann R (2000) Prognostic value of pololike kinase expression in melanomas. JAMA 283:479–480
Webb B, Sali A (2016) Comparative protein structure modeling using MODELLER. Curr Protoc Bioinformatics 47:5–6
Xu Y, Wang S, Hu Q, Gao S, Ma X, Zhang W, Shen Y, Chen F, Lai L, Pei J (2018) CavityPlus: a web server for protein cavity detection with pharmacophore modelling, allosteric site identification and covalent ligand binding ability prediction. Nucleic Acids Res 46:W374–W379
Yun SM, Moulaei T, Lim D, Bang JK, Park JE, Shenoy SR, Liu F, Kang YH, Liao C, Soung NK, Lee S, Yoon DY, Lim Y, Lee DH, Otaka A, Appella E, McMahon JB, Nicklaus MC, Burke TR Jr, Yaffe MB, Wlodawer A, Lee KS (2009) Structural and functional analyses of minimal phosphopeptides targeting the polo-box domain of polo-like kinase 1. Nat Struct Mol Biol 16:876–882
Zitouni S, Nabais C, Jana SC, Guerrero A, Bettencourt-Dias M (2014) Polo-like kinases: structural variations lead to multiple functions. Nat Rev Mol Cell Biol 15:433–452
Acknowledgements
This work was supported by a National Cancer Center Research Grant (1610020) and National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (NRF-2018R1A5A2023127 to BIL and NRF-2017R1D1A1B03034433 to SMB). KHC would like to thank KREONET (Korean Research Environment Open NETwork), which is managed and operated by KISTI (Korean Institute of Science and Technology Information).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bong, S.M., Moon, S., Cho, KH. et al. A NCAPG2-Derived Phosphopeptide Selectively Binds to the Polo-Box Domain of PLK1 and Inhibits Cancer Cell Proliferation. Int J Pept Res Ther 25, 1397–1403 (2019). https://doi.org/10.1007/s10989-018-9785-7
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10989-018-9785-7